Contribution of chemotherapy to the toxicity of pelvic irradiation

Amikar Sehdev, R. W. Marsh

Research output: Book/ReportBook


Pelvic malignancies encompass a diverse group of diseases and account for enormous morbidity and mortality worldwide. Given the established role of surgery and with better understanding of the potential synergy between chemotherapy and radiation, an era of combined modality therapy for these malignancies began to emerge in the 1990s. Many single institution and intergroup trials were conducted, establishing the role of combined modality therapy in pelvic malignancies by showing an improved survival, offering organ preservation and limiting surgical complications. However, these benefits accrued at the cost of increased acute toxicities as a result of the combined chemoradiation therapy. Interestingly, limited data suggest no significant increase in late/chronic toxicities, but ongoing and stringent follow-up will be critical to accurately define this issue which is of major interest to all cancer survivors. In the presence of limited data, it would be safe to assume that there is a higher rate of late toxicities given increased early effects lead to increased late effects and perhaps we would have seen these finding if the landmark chemoradiation trials would have collected data on late toxicities. In this chapter, we will review the currently existent literature on acute and late toxicities encountered by combining chemotherapy with radiation in the comprehensive therapy of pelvic malignancies.

Original languageEnglish (US)
PublisherSpringer New York
Number of pages24
ISBN (Electronic)9781493922178
ISBN (Print)9781493922161
StatePublished - Jan 1 2015
Externally publishedYes


  • Acute toxicity
  • Chemoradiation
  • Chemotherapy
  • Late toxicity
  • Overall survival
  • Pelvic cancer
  • Radiation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Contribution of chemotherapy to the toxicity of pelvic irradiation'. Together they form a unique fingerprint.

  • Cite this